USPRwire, Tue Nov 03 2015] GlobalData's clinical trial report, "Refractory Anemia With Excess Blasts
Global Clinical Trials Review, H2, 2015" provides an overview of Refractory Anemia With Excess Blasts
clinical trials scenario.
S Food and Drug Administration (FDA) on May 2, 2006 for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts
, refractory anemia with excess blasts
in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.